{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 20 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'will be notified about screening completion and will then not be allowed to screen additional', 'patients for this trial.', 'A log of all patients enrolled into the trial (i.e. who have signed informed consent) will be', 'maintained in the investigator site file (ISF) at the investigational site.', 'Rescreening of patients who are previously screen failed for the trial is allowed within 1-2', 'weeks for patients that fail due to FVC, spirometry may be repeated once. Rescreening for', 'administrative or other reasons must be discussed with the clinical monitor', '3.3.1', 'Main diagnosis for trial entry', 'To qualify for the trial, patients must have a diagnosis of Idiopathic Pulmonary Fibrosis (IPF)', 'according to American Thoracic Society (ATS), European Respiratory Society (ERS),', 'Japanese Respiratory Society (JRS), and Latin American Thoracic Association (ALAT)', 'criteria published in 2011, consistent with INPULSIS criteria. Patients must also have been', 'treated with nintedanib 150 mg BID at a stable dose for up to 30 months', 'Please refer to section 8.3.1 (Source Documents) for the documentation requirements', 'pertaining to the in- and exclusion criteria.', '3.3.2', 'Inclusion criteria', '1. Patients being treated with a stable dose of nintedanib 150 mg BID for up to 30 months.', 'Patients who have recently started nintedanib 150 mg BID and have started by the day of', 'randomization must be on nintedanib 150 mg BID a minimum of 10 days by the first day', 'of pulmonary rehabilitation.', '2. Age > 40 years at screening', '3. Women of childbearing potential (WOCBP)1 must be ready and able to use highly', 'effective methods of birth control per ICH M3 (R2) (R17-1399) that result in a low', 'failure rate of less than 1% per year when used consistently and correctly. A list of', 'contraception methods meeting these criteria is provided in the patient consent form', '4. Signed and dated written informed consent in accordance with ICH-GCP (International', 'Council on Harmonization and Good Clinical Practice) and local legislation prior to', 'admission to the trial', '5. Confirmed diagnosis of IPF according to 2011 ATS/ERS/JRS/ALAT guidelines by lung', 'biopsy or HRCT (based upon INPULSIS criteria (c02098775-02, c02155574-02), (if', 'biopsy only or HRCT done > 24 months prior to screening, a new HRCT to be done after', 'consent and prior to or up to 7 days after Visit 2 for quantitative lung fibrosis score (QLF)', 'for disease characterization)', '1', 'A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-', 'menopausal unless permanently sterile.', 'Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.', 'A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 21 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '6. Forced Vital Capacity (FVC) > 45% of predicted by the NHANES equation (R04-1001)', 'or equivalent (after discussion with Clinical Monitor), historical within past 30 days can', 'be used. Carbon monoxide Diffusion Capacity (DLco) (corrected for hemoglobin [Hgb])', '30-79% of predicted', '7. FEV1/FVC greater than/equal to 7', '8. Physically capable of performing both a 6 minute walk test and', '. must successfully complete the practice tests for the 6 minute walk', 'test, per the instructions', '3.3.3', 'Exclusion criteria', \"1. Major surgery (major according to the investigator's assessment) performed within 12\", 'weeks prior to randomization or planned within 6 months after screening, e.g. hip', 'replacement which could interfere with the ability to participate in pulmonary', 'rehabilitation.', '2. Any documented active or suspected malignancy or history of malignancy within 3 years', 'prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ', 'carcinoma of uterine cervix', '3. Patients who must or wish to continue the intake of restricted medications (see Section', '4.2.2.1) or any drug considered likely to interfere with the safe conduct of the trial', '4. Previous enrolment in this trial (except for rescreening as described in Section 3.3)', '5. Currently enrolled in another interventional investigational device or drug trial, or less', 'than 30 days since ending another investigational device or drug trial(s), or receiving', 'other investigational treatment(s)', \"6. Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes\", 'them an unreliable trial patient or unlikely to complete the trial', '7. Women who are pregnant, nursing, or who plan to become pregnant in the trial', '8. Previous participation in pulmonary rehabilitation program within 45 days prior to', 'signing consent', '3.3.4', 'Withdrawal of patients from therapy or assessments', 'Patients may potentially be withdrawn from trial treatment or from the trial as a whole', '(\"withdrawal of consent\") with very different implications, please see sections 3.3.4.1 and', '3.3.4.2 below.', 'Every effort should be made to keep the randomised patients in the trial: if possible', 'on', 'treatment, or at least to collect important trial data.', 'Measures to control the withdrawal rate include careful patient selection, appropriate', 'explanation of the trial requirements and procedures prior to randomization, as well as the', 'explanation of the consequences of withdrawal.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}